Newamsterdam Pharma
Clinical trials sponsored by Newamsterdam Pharma, explained in plain language.
-
New drug combo aims to slash stubborn heart risk factor
Disease control Recruiting nowThis study tests whether a new drug (obicetrapib) alone or with another drug (evolocumab) can lower a blood fat called Lp(a) that raises heart disease risk. About 69 adults with mildly high cholesterol and elevated Lp(a) will take the drugs for 16 weeks. The goal is to see if the…
Phase: PHASE2 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo pill aims to slash heart risk in diabetes patients
Disease control Recruiting nowThis study tests whether a new daily pill (obicetrapib, alone or combined with ezetimibe) can lower bad cholesterol more than a placebo in 300 adults with type 2 diabetes or metabolic syndrome who are already on standard cholesterol treatment. Participants take the study drug for…
Phase: PHASE3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Can a pill boost your Body's antioxidant defenses? new study investigates.
Knowledge-focused Recruiting nowThis study tests whether the drug obicetrapib can increase levels of key antioxidants (like lutein and vitamin E) in the blood and eyes of healthy people. One hundred volunteers will take either the drug or a placebo daily for 4 months. The goal is to understand how obicetrapib a…
Phase: PHASE2 • Sponsor: NewAmsterdam Pharma • Aim: Knowledge-focused
Last updated May 26, 2026 06:25 UTC